EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacological manipulation of liver fibrosis progression using novel HDAC 6 inhibitors

Maria Teresa Borrello, Dusan Ruzic, Hannah Paish, Eleanor Graham, Amy L Collins, Rebecca Scott, Sam Higginbotham, Branko Radovic, Glyn Nelson, David Bulmer, Lee A Borthwick, Stuart M Robinson und 14 weitere

The FEBS Journal · 2025

DOI: 10.1111/febs.70062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FEBS Journal, 2025. Verfasst von Maria Teresa Borrello und 25 weiteren Autor:innen. Beteiligte Einrichtung: Newcastle Fibrosis Research Group, Bioscience Institute, Faculty of Medical Sciences, Newcastle University, UK. Hauptthemen laut MEDLINE: Histone Deacetylase 6, Liver Cirrhosis, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science, Technological Development and Innovation, Republic of Serbia, National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC), Rosetrees Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic liver injury characterized by unresolved hepatitis leads to fibrosis, potentially progressing to cirrhosis and hepatocellular carcinoma. Effective treatments for halting or reversing liver fibrosis are currently lacking. This study investigates the potential of HDAC6 as a therapeutic target in liver fibrosis. We synthesized two selective HDAC6 inhibitors, DR‐3 and FDR2, and assessed their effects on hepatic stellate cell (HSC) activation and liver fibrosis using human precision cut liver slices (hPCLS). Molecular docking, deacetylation inhibition assays, and various cellular assays were employed to evaluate the specificity and anti‐fibrotic efficacy of these inhibitors. DR‐3 and FDR2 demonstrated high selectivity for HDAC6 over HDAC1, significantly inhibiting HSC activation markers and fibrogenic gene expression. Both inhibitors increased acetylation of α‐tubulin and suppressed TGF‐β1‐induced SMAD signaling in HSCs. In human precision cut liver slices (hPCLS), DR‐3 and FDR2 reduced fibrogenic protein levels and collagen deposition. The selective inhibition of HDAC6 by DR‐3 and FDR2 effectively reduces HSC activation and fibrogenesis in liver models, supporting further investigation of HDAC6 inhibitors as potential anti‐fibrotic therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase 6Liver CirrhosisHistone Deacetylase InhibitorsHumansHepatic Stellate CellsMolecular Docking SimulationAcetylationSignal TransductionLiverDisease ProgressionTubulinTransforming Growth Factor beta1Hydroxamic AcidsAnimalsHistone Deacetylase 1

Stichwörter der Autor:innen

HDAC6 inhibitorshistone deacetylase inhibitorshuman precision cut liver slicesliver fibrosistherapy

Substanzen

Histone Deacetylase 6Histone Deacetylase InhibitorsHDAC6 protein, humanTubulinTransforming Growth Factor beta1Hydroxamic AcidsHistone Deacetylase 1

Autor:innen und Institutionen

  • Newcastle Fibrosis Research Group, Bioscience Institute, Faculty of Medical Sciences, Newcastle University, UK.
  • School of Pharmacy and Pharmaceutics, Faculty of Health Sciences and Wellbeing, University of Sunderland, UK.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Serbia.
  • Bioimaging Unit, Faculty of Medical Sciences, Newcastle University, UK.
  • FibroFind, Newcastle upon Tyne, UK.
  • Department of Hepatobiliary Surgery, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK.

ORCID-Profile: Jelena Mann

Förderung

  • Ministry of Science, Technological Development and Innovation, Republic of Serbia
  • National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC)
  • Rosetrees Trust
  • EU Regional Development Fund
  • Cancer Research UK
  • Medical Research Council
  • National Institute for Health and Care Research

Zitieren

APA

Borrello, M. T., Ruzic, D., Paish, H., Graham, E., Collins, A. L., Scott, R., Higginbotham, S., Radovic, B., Nelson, G., Bulmer, D., Borthwick, L. A., Robinson, S. M., French, J., Moir, J., White, S. A., Wilson, C., Pandanaboyana, S., Hammond, J., Thakkar, R., …, & Mann, J. (2025). Pharmacological manipulation of liver fibrosis progression using novel HDAC 6 inhibitors. The FEBS Journal. https://doi.org/10.1111/febs.70062

Vancouver

Borrello MT, Ruzic D, Paish H, Graham E, Collins AL, Scott R, et al. Pharmacological manipulation of liver fibrosis progression using novel HDAC 6 inhibitors. The FEBS Journal. 2025. doi:10.1111/febs.70062

BibTeX
@article{Borrello2025,
  author = {Borrello, Maria Teresa and Ruzic, Dusan and Paish, Hannah and Graham, Eleanor and Collins, Amy L and Scott, Rebecca and Higginbotham, Sam and Radovic, Branko and Nelson, Glyn and Bulmer, David and Borthwick, Lee A and Robinson, Stuart M and French, Jeremy and Moir, John and White, Steve A and Wilson, Colin and Pandanaboyana, Sanjay and Hammond, John and Thakkar, Rohan and Alrawashdeh, Wasfi and Figueiredo, Rodrigo and Petkovic, Milos and Nikolic, Katarina and Oakley, Fiona and Mann, Derek A and Mann, Jelena},
  title = {Pharmacological manipulation of liver fibrosis progression using novel HDAC 6 inhibitors},
  journal = {The FEBS Journal},
  year = {2025},
  doi = {10.1111/febs.70062}
}
Kostenlos starten →